TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers report that oligodendrocytes, cells that maintain the brain’s myelin coating, may become dysfunctional with age. Human brain-tissue findings and experiments in mice link lower NRF2 activity in these cells to abnormal myelin, loss of large nerve fibers and poorer cognitive changes; whether targeting this pathway can help older adults remains unknown.
A study led by researchers at the University of Edinburgh and the UK Dementia Research Institute found that age-related dysfunction in oligodendrocytes—cells that maintain the protective myelin around nerve fibers—may contribute to cognitive decline. The research, published in Nature Medicine, links lower levels of the cell-protective protein NRF2 with abnormal myelin and nerve-fiber loss in human brain tissue, while mouse experiments provide evidence that reducing NRF2 in these cells can cause similar changes.
The human analysis drew on the Lothian Birth Cohort 1936, whose members have had their cognitive abilities tracked from childhood into older age. Between ages 70 and 82, participants were assessed on memory, information-processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional testing after age 70; almost all showed some decline, but the pace differed.
Researchers examined brain tissue collected after death from a subset of participants. People who had experienced greater cognitive decline tended to have fewer large nerve fibers and an abnormal accumulation of myelin, the insulation that helps electrical signals travel along those fibers. The tissue findings were associated with the rate of decline, not simply with a person’s cognitive test performance at one age.
The team then investigated oligodendrocytes, which produce and maintain myelin. Participants with more severe decline had lower NRF2 levels in these cells. In mice, specifically reducing oligodendrocyte NRF2 led to excessive myelin, loss of large nerve fibers and smaller improvements in cognitive performance as the animals aged. The experiments support a role for NRF2 in the process, but do not establish that the same mechanism explains cognitive decline in every person.
A New Target in Brain Aging
The findings challenge the simple view that myelin-producing cells are always protective. They suggest that changes in the cells responsible for maintaining nerve insulation may be part of the biology associated with age-related cognitive decline. That could broaden research beyond neurons themselves to the cells and structures that help them communicate.
The work also identifies the NRF2 pathway as a possible focus for treatment research. The source report notes that drugs targeting this pathway are already used for other neurological conditions, including multiple sclerosis. That makes it a potentially testable avenue, but it does not mean those medicines are proven to prevent or treat ordinary age-related cognitive decline. Any use for that purpose would require evidence from research specifically involving older adults and this condition.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The cohort’s long-running assessments gave researchers a way to compare differences in cognitive change across decades, rather than relying only on a single test taken late in life. Linking those records to post-mortem tissue let the team examine whether brain features were associated with the pace of decline. Because the tissue came from a subset of participants after death, the human findings show an association and cannot by themselves establish cause.
The mouse experiments addressed a different question: whether reducing NRF2 in oligodendrocytes could produce related brain changes. The resulting myelin and nerve-fiber abnormalities resembled those observed in human tissue, and the mice showed reduced improvement on cognitive tests with age. Together, the human and animal evidence supports further investigation, but animal results do not show that a treatment will work in people.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
As an affiliate, we earn on qualifying purchases.
Human Treatment Evidence Is Missing
The study does not show that reduced NRF2 activity is the sole cause of cognitive decline, or that changing the pathway would reverse damage in people. The human evidence comes from associations between cognitive trajectories and tissue examined after death; the more direct tests were performed in mice. It is also unclear how broadly the results apply beyond this cohort and the specific brain changes studied.
Although existing medicines act on the NRF2 pathway, the supplied report does not establish that any such drug is safe or effective for age-related cognitive decline. It gives no trial results in older adults without multiple sclerosis, nor a timeline for testing the approach. Whether abnormal myelin is a driver of decline, a consequence of other aging processes, or part of a more complex interaction remains under investigation.
cognitive decline support supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the NRF2 Pathway in People
The immediate next step is further research to establish how NRF2 changes affect oligodendrocyte function over time and whether the pathway can be altered safely in ways that preserve nerve fibers. Researchers would also need to determine whether the human tissue patterns can be measured in living people and whether they predict future cognitive change.
Before an existing NRF2-targeting medicine could be considered for older adults with cognitive decline, researchers would need clinical studies designed for that group. Such work would have to assess both cognitive outcomes and safety. The source report does not announce a clinical trial or specify when one might begin, so a treatment application remains a possibility rather than a current option.
oligodendrocyte health supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which brain cells did the study examine?
It focused on oligodendrocytes, cells that produce and maintain myelin, the protective coating around nerve fibers.
What did researchers find in human brain tissue?
Among the participants whose tissue was examined, greater cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes.
Do the findings prove that low NRF2 causes cognitive decline in people?
No. The human results show associations. Experiments that reduced NRF2 and produced related changes were conducted in mice, so the findings do not prove the same causal process in people.
Could existing medicines treat age-related cognitive decline?
The study points to a pathway targeted by medicines used for other conditions, but it does not show that those drugs treat age-related cognitive decline. Clinical research in the relevant population would be needed.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
